Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

The poster titled, "Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment," is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre- Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The poster is available on the Scientific Publications page of the Company's website. "The findings from this preclinical study add to our growing body of encouraging data for PALI-2108 and further bolster our ...